This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer-related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.
NCT# 03080883
